Alterity Therapeutics (ASX:ATH) Receipts from Customers: A$0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ATH Alterity Therapeutics Ltd ASX:ATH
28 GF Score
Price A$0.55
View Full Analysis

What is Alterity Therapeutics Receipts from Customers?

Alterity Therapeutics ASX:ATH +2.83% 28 Receipts from Customers is A$0.00 Mil as of Mar. 2026. GuruFocus rates ASX:ATH with a GF Score™ of 28/100.

Alterity Therapeutics's Receipts from Customers for the three months ended in Mar. 2026 was A$0.00 Mil.

Alterity Therapeutics's Receipts from Customers for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.00 Mil.

Alterity Therapeutics Receipts from Customers Historical Data

* Premium members only.

The historical data trend for Alterity Therapeutics's Receipts from Customers can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics Receipts from Customers Chart

Alterity Therapeutics Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Receipts from Customers
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Alterity Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Receipts from Customers Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:ATH
28GF Score
Alterity Therapeutics Ltd ASX:ATH
Receipts from Customers is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alterity Therapeutics Receipts from Customers Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Receipts from Customers represents payment received from customers in the direct cash flow method.

Receipts from Customers for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Receipts from Customers of A$0.00 Mil mean?
Alterity Therapeutics (ASX:ATH) has a Receipts from Customers of A$0.00 Mil as of Mar. 2026. Receipts from Customers represents payment received from customers in the direct cash flow method. View historical data for Alterity Therapeutics and its competitors.
Is Alterity Therapeutics' Receipts from Customers too high?
Alterity Therapeutics' current Receipts from Customers is A$0.00 Mil. Overall, Alterity Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' Receipts from Customers compare to VRTX and REGN?
Alterity Therapeutics' Receipts from Customers of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receipts from Customers for a Biotechnology company?
A good Receipts from Customers depends on the Biotechnology industry context. However, Receipts from Customers should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receipts from Customers mean?
A high Receipts from Customers can signal that a stock is expensive relative to its fundamentals. Receipts from Customers represents payment received from customers in the direct cash flow method. View historical data for Alterity Therapeutics and its competitors. Alterity Therapeutics's current Receipts from Customers is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (ASX:ATH) has a current Receipts from Customers of A$0.00 Mil. The current Receipts from Customers is A$0.00 Mil. Alterity Therapeutics' overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receipts from Customers calculated?
Receipts from Customers is calculated from a company's financial statements. For Alterity Therapeutics (ASX:ATH), the current Receipts from Customers is A$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alterity Therapeutics Business Description

Other Exchanges ATHE:USAPBN:Germany
Address 350 Collins Street, Suite 4, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
28GF Score

Get the complete analysis for ASX:ATH

Receipts from Customers is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.55
Price